Pharmascience Canada has announced the launch of Pr pms-PALBOCICLIB, a new treatment of certain types of breast cancer.
About Pr pms-PALBOCICLIB
Pr pms-PALBOCICLIB (palbociclib) is indicated for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with:
- An aromatase inhibitor: As the initial endocrine-based therapy for post-menopausal women or men.
- Fulvestrant: For patients experiencing disease progression after previous endocrine therapy. Pre- or perimenopausal women receiving this treatment must also be administered a luteinizing hormone-releasing hormone (LHRH) agonist.
Pr pms-PALBOCICLIB is now available in Canada in three dosage strengths:
- 75 mg: Packaged in three weekly blister packs, totaling 21 tablets.
- 100 mg: Packaged in three weekly blister packs, totaling 21 tablets.
- 125 mg: Packaged in three weekly blister packs, totaling 21 tablets.
This medication is the generic equivalent of IBRANCE® and adds to Pharmascience’s portfolio of oncology treatments.
Leadership Commentary
Mike Dutton, Vice-President and General Manager of Pharmascience Canada, expressed the company’s dedication to providing innovative pharmaceutical solutions. “The launch of Pr pms-PALBOCICLIB demonstrates our commitment to supporting Canadian patients and the local healthcare industry. Our team has worked diligently to ensure this medication meets the highest standards of quality, offering a valuable new option for breast cancer treatment.”
Advancing Pharmaceutical Excellence
This latest development underscores Pharmascience Canada’s expertise in developing specialty medications and its commitment to enhancing patient outcomes.
For more information about Pr pms-PALBOCICLIB, healthcare professionals are encouraged to consult official prescribing information.
